HeartBeam Inc. Advances Cardiac Monitoring with New Patents
TL;DR
HeartBeam Inc. secures a competitive edge with two new U.S. patents, enhancing its remote cardiac diagnostics technology and expanding its intellectual property portfolio.
HeartBeam's 3D ECG device and rhythm analysis algorithm utilize chest and finger electrodes for high-fidelity signal collection and arrhythmia identification, currently under FDA review.
HeartBeam's innovative cardiac care technology enables early detection of heart conditions outside medical facilities, improving patient outcomes and accessibility to healthcare.
Discover how HeartBeam is revolutionizing cardiac care with its cable-free 3D ECG device and AI-enhanced diagnostic accuracy, backed by 20 issued patents.
Found this article helpful?
Share it with your network and spread the knowledge!
HeartBeam Inc. (NASDAQ: BEAT) has recently been granted two new U.S. patents, enhancing its portfolio in the field of remote cardiac diagnostics. These patents cover the company's compact, cable-free 3D ECG device and a rhythm analysis algorithm designed to detect arrhythmias through continuous signal input. This development is pivotal as it underscores HeartBeam's commitment to advancing cardiac care technology, enabling more accurate and accessible heart health monitoring outside traditional medical facilities.
The 3D ECG device utilizes chest and finger electrodes to capture high-fidelity signals in three dimensions, facilitating on-demand symptom recording and the synthesis of 12-lead ECGs. Currently under FDA review, the device's software is supported by data from the VALID-ECG pivotal study. Meanwhile, the rhythm algorithm enhances diagnostic precision by triggering targeted data collection during abnormal rhythm detection, applicable across various cardiac monitoring systems.
With a total of 20 issued patents and 34 additional filings, HeartBeam is positioning itself as a leader in digital cardiac care innovation. The company's future plans include integrating AI capabilities to further improve diagnostic accuracy, promising a transformative impact on how cardiac conditions are monitored and managed globally.
Curated from InvestorBrandNetwork (IBN)
